In order to maintain the trust of the company’s stakeholders, Orphazyme is committed to ensure transparent and good corporate governance. As a company listed on Nasdaq Copenhagen A/S, Orphazyme is subject to the Recommendations on Corporate Governance from May 2013 (as amended November 2014).
The Recommendations on Corporate Governance are best practice guidelines for the management of companies admitted to trading on a regulated market. Orphazyme intends to comply with the Recommendations on Corporate Governance in all material respects, however, due to the current size of the Company and the nature of its present operations, the company has opted to deviate from the Recommendations in the following areas:
- Orphazyme has decided only to publish half-yearly financial reports;
- the current articles of association does not stipulate a retirement age for Orphazyme’s board of directors;
- share options are included in the remuneration of the board of directors; and
- share-based instruments that are granted to board members have a maturity of one year from the date of allocation;
Orphazyme’s corporate governance statement includes a summary of the company’s governance structure, Orphazyme’s position on the Recommendations on Corporate Governance as well as a complete list of the company’s comments to each recommendation. The corporate governance statement and other key documents are available below.